NYLIM
RGNX icon

New York Life Investment Management’s Regenxbio RGNX Stock Holding History

New York Life Investment Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18,404
Closed -$330K – 1494
2023
Q4 		$330K Sell
18,404
-424
-2% -$7.47K ﹤0.01% 1157
2023
Q3 		$310K Sell
18,828
-2,967
-14% -$53.8K ﹤0.01% 1124
2023
Q2 		$436K Sell
21,795
-3,135
-13% -$60.4K ﹤0.01% 867
2023
Q1 		$471K Buy
+24,930
New +$552K 0.01% 1067

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

New York Life Investment Management's RGNX Position: Q1 2024 in Review

New York Life Investment Management sold out of Regenxbio (RGNX) in Q1 2024, closing a stake of 18,404 shares — an estimated $330K sold.

New York Life Investment Management first reported a position in RGNX in Q1 2023 and held it in 4 quarters. The position peaked at $471K in Q1 2023. 188 funds tracked by Wall St. Rank hold RGNX as of Q1 2024.

  • New York Life Investment Management reported no remaining Regenxbio position as of Q1 2024 after selling out during the quarter.
  • New York Life Investment Management sold 18,404 Regenxbio shares in Q1 2024, an estimated $330K.
  • New York Life Investment Management first reported a position in Regenxbio in Q1 2023 and held it in 4 quarters.
  • New York Life Investment Management's Regenxbio position peaked at $471K in Q1 2023.
  • 188 funds tracked by Wall St. Rank held Regenxbio as of Q1 2024.

Based on New York Life Investment Management's 13F filing for Q1 2024, filed 6 May 2024.